Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
US9580456B2 · kind B2 · utility
6Cited by
6References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2013 |
| Grant date | Feb 28, 2017 |
| Priority date | — |
| Expiry date | Oct 30, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.